BuzzSparks.org

MedImmune Ventures


Venture Capital

MedImmune Ventures is a wholly owned venture capital fund within the AstraZeneca/MedImmune group of companies. It was created in 2002 to leverage MedImmune’s expertise in discovering, developing and commercializing biotechnology products, as...

Founded in 1987
Homepage:

HQ

20878 One MedImmune Way

Gaithersburg
Gaithersburg
USA MD

Phone: (301) 398-4624

Updated on Apr 15, 2013
MedImmune Ventures at CrunchBase
Franklin H. Top Vice President
Joseph Amprey Senior Managing Director
Ron Laufer Senior Managing Director
Michael Gutch Managing Director
Melissa Alban Administrative Assistant III
Isai Peimer Principal
Samuel Wu Managing Director
Tyrell Rivers Senior Associate
Sam Wu Managing Director
Past
David Mott President and Chief Executive Officer

September, 2013

MedImmune Ventures invested $7M in Inotek Pharmaceuticals as debt_round round

February, 2013

MedImmune Ventures invested $9M in Catabasis Pharmaceuticals as unattributed round

November, 2012

MedImmune Ventures invested $37.5M in Applied Genetics Technologies Corporation as a Series B round

MedImmune Ventures invested $50M in Ambit Biosciences as unattributed round

July, 2012

MedImmune Ventures invested $12M in Coferon as a Series B round

December, 2011

MedImmune Ventures invested $8M in Catabasis Pharmaceuticals as a Series A round

June, 2011

MedImmune Ventures invested $30M in Ambit Biosciences as a Series D round

June, 2010

MedImmune Ventures invested $15M in Corridor Pharmaceuticals as a Series A round

MedImmune Ventures invested $18M in Inotek Pharmaceuticals as a Series D round

April, 2010

MedImmune Ventures invested $39M in Catabasis Pharmaceuticals as a Series A round

January, 2010

MedImmune Ventures invested $51.6M in VentiRx Pharmaceuticals as a Series A round

November, 2009

MedImmune Ventures invested $30M in Virdante Pharmaceuticals as a Series A round

MedImmune Ventures invested $4.6M in Arginetix as a Series B round

October, 2009

MedImmune Ventures invested $10.8M in Corridor Pharmaceuticals as a Series A round

June, 2009

MedImmune Ventures invested $30M in VaxInnate as a Series D round

MedImmune Ventures invested $11.8M in Applied Genetics Technologies Corporation as a Series C round

March, 2009

MedImmune Ventures invested $8M in NKT Therapeutics as a Series A round

January, 2009

MedImmune Ventures invested $25M in Rib-X Pharmaceuticals as unattributed round

MedImmune Ventures invested $22M in Hydra Biosciences as a Series D round

October, 2008

MedImmune Ventures invested $2.3M in Arginetix as angel investor

April, 2008

MedImmune Ventures invested $28M in LigoCyte Pharmaceuticals as a Series B round

March, 2008

MedImmune Ventures invested $30M in BrainCells as a Series B round

January, 2007

MedImmune Ventures invested $35M in Sequoia Pharmaceuticals as a Series C round

October, 2006

MedImmune Ventures invested $40M in VaxInnate as a Series C round

June, 2006

MedImmune Ventures invested $55M in VLST Corporation as a Series B round

May, 2006

MedImmune Ventures invested $43.8M in Avidia as a Series C round

May, 2005

MedImmune Ventures invested $28.5M in Avidia as a Series B round

November, 2003

MedImmune Ventures invested $27M in Applied Genetics Technologies Corporation as a Series B round

1987

MedImmune Ventures was founded in 1987